Wells Fargo analyst Derek Archila raised the firm’s price target on C4 Therapeutics (CCCC) to $10 from $5 and keeps an Overweight rating on the shares. The firm thinks cemsidomide’s updated data at the 75ug and 100ug doses presented this weekend at the IMS meeting suggest better efficacy/safety than BMS programs and should allow for future combos in earlier-line MM. Wells thinks shares should trade up on the news.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics price target raised to $10 from $8 at Barclays
- C4 Therapeutics Reports Promising Phase 1 Trial Results
- C4 Therapeutics: Balancing Promise and Competition in the Multiple Myeloma Market
- C4 Therapeutics presents data from Phase 1 trial of cemsidomide
- C4 Therapeutics initiated with an Overweight at Barclays